Literature DB >> 10336417

Selective inhibition of protein kinase C isozymes by Fas ligation.

C Y Chen1, D V Faller.   

Abstract

Activation of protein kinase C (PKC) can protect cells from apoptosis induced by various agents, including Fas ligation. To elucidate a possible interaction between Fas-mediated apoptotic signals and activation-related protective signals, we investigated the impact of Fas ligation on PKC activity. We demonstrate that engagement of Fas on human lymphoid Jurkat cells triggered apoptosis, and Fas ligation resulted in partial blockade of cellular PKC activity. The phorbol 12-myristate 13-acetate-mediated translocation of PKCtheta from the cytoplasm to the membrane was inhibited by treatment with anti-Fas antibody, whereas the translocation of PKCalpha or epsilon was not affected. In vitro kinase assay of PKCalpha or epsilon phosphotransferase activity demonstrated that Fas ligation inhibited the ability of PKCalpha to phosphorylate histone H1 as substrate but did not inhibit epsilon isozyme activity. This inhibition of PKCalpha activity mediated by Fas ligation was reversed by okadaic acid, a phosphatase inhibitor, suggesting the involvement of a member of the protein phosphatase 2A subfamily in this component of Fas signaling. Identical patterns of PKC isozyme inhibition were obtained using mouse thymoma cells overexpressing the fas gene (LF(+)). These results suggest that the selective inhibition of a potentially protective, PKC-mediated pathway by Fas activation may, to some extent, contribute to Fas-induced apoptotic signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336417     DOI: 10.1074/jbc.274.22.15320

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Proinflammatory consequences of transgenic fas ligand expression in the heart.

Authors:  D P Nelson; E Setser; D G Hall; S M Schwartz; T Hewitt; R Klevitsky; H Osinska; D Bellgrau; R C Duke; J Robbins
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.

Authors:  Zhihong Chen; Lora W Forman; Kenneth A Miller; Brandon English; Asami Takashima; Regine A Bohacek; Robert M Williams; Douglas V Faller
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

3.  PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.

Authors:  Shuhua Xia; Zhihong Chen; Lora W Forman; Douglas V Faller
Journal:  Cell Signal       Date:  2008-12-10       Impact factor: 4.315

4.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.

Authors:  Karine Belguise; Gail E Sonenshein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Ceramide inhibits PKCθ by regulating its phosphorylation and translocation to lipid rafts in Jurkat cells.

Authors:  Rouba Hage-Sleiman; Asmaa B Hamze; Aimée F El-Hed; Randa Attieh; Lina Kozhaya; Sarah Kabbani; Ghassan Dbaibo
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

6.  Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism.

Authors:  Dashnamoorthy Ravi; Harish Muniyappa; Kumuda C Das
Journal:  Mol Cell Biochem       Date:  2007-10-12       Impact factor: 3.396

7.  Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy.

Authors:  Ranjana Arya; Vishram Kedar; Jae Ryoung Hwang; Holly McDonough; Hui-Hua Li; Joan Taylor; Cam Patterson
Journal:  J Cell Biol       Date:  2004-12-13       Impact factor: 10.539

8.  Resveratrol induces long-lasting IL-8 expression and peculiar EGFR activation/distribution in human keratinocytes: mechanisms and implications for skin administration.

Authors:  Saveria Pastore; Daniela Lulli; Riccardo Maurelli; Elena Dellambra; Chiara De Luca; Liudmila G Korkina
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.